KDR and renal cell carcinoma: These include monoclonal antibodies (for example, bevacizumab) or small molecules (for example, anti-VEGFR tyrosine kinase inhibitors).[8] After early-phase trials established optimal dosing and safety profiles and received approval for the treatment of advanced renal cell carcinoma, pazopanib was studied in STS.